Methods for inhibiting tumor cell proliferation

Details Methods for inhibiting tumor cell proliferation Methods for inhibiting tumor cell proliferation

2006-10-17

2006-10-17

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S329000

Reexamination Certificate

active

07122523

ABSTRACT:
The present invention provides methods, compounds, and pharmaceutical compositions for inhibiting tumor cell proliferation, by administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2type 2 receptor agonists to a subject.

REFERENCES:
patent: 3750653 (1973-08-01), Simon
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 5015629 (1991-05-01), diZerega
patent: 5629292 (1997-05-01), Rodgers et al.
patent: 5693616 (1997-12-01), Krstenansky et al.
patent: 5716935 (1998-02-01), Rodgers et al.
patent: 5834432 (1998-11-01), Rodgers et al.
patent: 5955430 (1999-09-01), Rodgers et al.
patent: 5977159 (1999-11-01), Fandriks et al.
patent: 5981568 (1999-11-01), Kunz et al.
patent: 6017522 (2000-01-01), Butterfield et al.
patent: 6096709 (2000-08-01), Rodgers et al.
patent: 6110895 (2000-08-01), Rodgers et al.
patent: 6165978 (2000-12-01), Rodgers et al.
patent: 6177407 (2001-01-01), Rodgers et al.
patent: 2003/0203834 (2003-10-01), Tallant et al.
patent: WO 9003768 (1990-04-01), None
patent: WO 99/45945 (1999-09-01), None
Bailar et al., Cancer Undefeated, New England Journal of Medicine, vol. 336, No. 22, pp. 1569-1574.
Gura, T., Science, 1997, vol. 278, No. 5340, pp. 1041-1042.
Bailar et al. (New England Journal of Medicine, 1997, vol. 336, No. 22, pp. 1569-1574.
Bailar III, et al., (1997), N. Engl. J. Med., “Cancer Undefeated”, vol. 336 (22), pp. 1569-1574.
Kunapuli, et al., (1987), Circulation Research, “Molecular cloning of human angiotensinogen CDNA and evidence for the presence of its mRNA in rat heart”, vol. 60 (5), pp. 786-790.
Clouston, et al., (1988), Genomics, “Molecular cloning of the mouse angiotensinogen gene”, vol. 2, pp. 240-248.
Kageyama, et al., (1984), Biochemistry, “Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence”, vol. 23, pp. 3603-3609.
Ohkubo, et al., (1983), Proc. Natl. Acad. Sci., Cloning and sequence analysis of cDNA for rat angiotensinogen, vol. 80, pp. 2196-2200.
Dzau, et al., (1989), J. Mol. Cell. Cardiol., “Molecular mechanism of angiotensin in the regulation of vascular and cardiac growth”,vol. 21, pp. S7 (Supp III).
Berk, et al., (1989), Hypertension, “Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells”, vol. 13 (4), pp. 305-314.
Kawahara, et al., (1988), BBRC, “Angiotensin II induces expression of the C-FOS gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells”,vol. 150 (1), pp. 52-59.
Naftilan, et al., (1989), J. Clin. Invest., “Induction of platelet-derived growth factor A-chain and c-mycgene expressions by angiotensin II in cultured rat vascular smooth muscle cells”, vol. 83, pp. 1419-1424.
Taubman, et al., (1989), J. Biol. Chem., “Angiotensin II induces c-fosmRNA in aortic smooth muscle”, vol. 264 (1), pp. 526-530.
Nakahara, et al., (1992), BBRC, “Identification of three types of PDGF-A chain gene transcripts in rabbit vascular smooth muscle and their regulated expression during development and by angiotensin II”, vol. 184 (2), pp. 811-818.
Stouffer and Owens, (1992), Circ. Res., “Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-β”, vol. 70 (4), pp. 820-828.
Wolf, et al., (1992), Am. J. Pathol., “Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells”, vol. 140 (1), pp. 95-107.
Bell and Madri, (1990), Am. J. Pathol., “Influence of the angiotensin sustem on endothelial and smooth muscle cell migration”, vol. 137 (1), pp. 7-12.
Fernandez, et al., (1985), J. Lab. Clin. Med., “Neovascularization produced by angiotensin II”, vol. 105(2), p. 141.
LeNoble, et al., (1991), Eur. J. Pharmacol., “Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo”, vol. 195, pp. 305-306.
Shanugam, et al., (1995), Am. J. Physiol., “Expression of angiotensin II AT2receptor mRNA during development of rat kidney and adrenal gland”, vol. 268, pp. F922-F930.
Helin, et al., (1997), Annals of Medicine, “The role of angiotensin receptors in cardiovascular diseases”, vol. 29, pp. 23-29.
Bedecs, et al., (1997), Biochem J., “Angiotensing II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase”, vol. 325, pp. 449-454.
Stecklings, et al., (1996), Biochem. Biophys. Res. Commun., “Angiotensin II stimulates proliferation of primary human keratinocytes via a Non-AT1, Non-AT2angiotensin receptor”, vol. 229, pp. 329-333.
Ferrario, et al., (1998), J. Am. Soc. Nephrol, “Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis”, vol. 9, pp. 1716-1722.
Iyer, et al., (1998), Hypertension, “Vasodepressor actions of angiotensin—(1-7) unmasked during combined treatment with lisinopril and losartan”, vol. 31, pp. 699-705.
Freeman, et al., (1996), Hypertension, “Angiotensin-(1-7) inhibits vascular smooth muscle cell growth”, vol. 28 (1), pp. 104-108.
Ambühl, et al., (1994), Brain Res. Bull., “[7-D-ALA]-Angiotensin-(1-7): Selective antagonism of angiotensin-(1-7) in the rat paraventricular nucleus”, vol. 35 (4), pp. 289-291.
Ferrario, et al., (1997), Hypertension, “Counterregulatory actions of angiotensin-(1-7)”, vol. 30, pp. 535-541.
Strawn, et al., (1999), Hypertension, “Angiotensin-(1-7) reduces smooth muscle growth after vascular injury”, vol. 33, pp. 207-211.
Mueck, et al., (1999), Int. J. Clin. Pharmacol. Ther., “Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery”, vol. 37(7), pp. 365-366.
Hii, et al., (1998), Br. J. Cancer, “Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma”, vol. 77(6), pp. 880-883.
Small Jr., et al., (1997), Breast Cancer Res. Treat., “Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture”, vol. 44(3), pp. 217-224.
Reddy, et al., (1995), Proc. Soc. Exp. Biol. Med., “Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells”, vol. 210(3), pp. 221-226.
Kunert-Radek and Pawlikowski, (1992), “Angiotensin II stimulation of the rat pituitary tumoral cell proliferationin vitro”, Biochem. Biophys. Res. Commun., vol. 183(1), pp. 27-30.
Speth and Kim, (1990), BBRC, “Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6angiotensin II”, vol. 169 (3), pp. 997-1006.
Catalioto, et al., (1994), Eur. J. Pharmacol., “Angiotensins induce the release of prostacyclin from rabbit vas deferens: evidence for receptor heterogeneity”, vol. 256, pp. 93-97.
Bryson, et al., (1992), Eur. J. Pharmacol., Induction of the angiotensin AT2receptor subtype expression by differentiation of the neuroblastoma X glioma hybrid, NG-108-15, vol. 225, pp. 119-127.
Janiak, et al., (1992), Hypertension, “Role of angiotensin subtype 2 receptor in neointima formation after vascular injury”, vol. 20 (6), pp. 737-745.
Prescott, et al., (1991), Am. J. Pathol., “Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1receptor antagonist”, vol. 139 (6), pp. 1291-1296.
Kauffman, et al., (1991), Life Sci., “Losartan, a nonpeptide angiotensin II (ANGII) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid

Affiliated with

Also associated with

Rating

Methods for inhibiting tumor cell proliferation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for inhibiting tumor cell proliferation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting tumor cell proliferation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3660521